Fisher Asset Management Boosts Eli Lilly Stake Amid GLP-1 Expansion
Key Takeaways
- Fisher Asset Management LLC increased its position in Eli Lilly and Company by 3.5% during the third quarter, acquiring an additional 150,595 shares.
- The move brings the firm's total holdings to over 4.45 million shares, signaling continued institutional confidence in the pharmaceutical giant's growth trajectory.
Mentioned
Key Intelligence
Key Facts
- 1Fisher Asset Management acquired 150,595 additional shares of Eli Lilly (LLY) in Q3.
- 2The firm's total holdings in Eli Lilly now stand at 4,453,062 shares.
- 3This transaction represents a 3.5% increase in Fisher's total position in the company.
- 4Eli Lilly is currently the world's most valuable healthcare company by market capitalization.
- 5The acquisition was disclosed in a recent filing with the Securities and Exchange Commission (SEC).
Eli Lilly and Company
Company- Ticker
- LLY
- Headquarters
- Indianapolis, IN
- Key Products
- Mounjaro, Zepbound, Kisunla
A global pharmaceutical leader specializing in diabetes, obesity, oncology, and immunology.
Analysis
Fisher Asset Management’s decision to increase its stake in Eli Lilly and Company (LLY) by 3.5% during the third quarter marks a significant reinforcement of institutional confidence in the pharmaceutical giant. By acquiring an additional 150,595 shares, the firm now holds a total of 4,453,062 shares, a position that reflects the broader market's bullish outlook on Eli Lilly’s dominant role in the metabolic and neurological health sectors. This move by Fisher, a firm known for its long-term value-oriented strategies, suggests that the current valuation of Eli Lilly still offers attractive upside despite its meteoric rise over the past two years.
The primary driver behind this institutional interest remains Eli Lilly’s leadership in the GLP-1 receptor agonist market. With Mounjaro (for diabetes) and Zepbound (for obesity) consistently outperforming sales expectations, the company has established a formidable duopoly alongside Novo Nordisk. However, Lilly has distinguished itself through aggressive manufacturing expansions, committing billions to new facilities in Indiana, North Carolina, and Germany to resolve the supply constraints that have plagued the industry. Investors like Fisher are likely betting that Lilly’s superior supply chain management and its robust pipeline of next-generation oral GLP-1s will allow it to capture a larger share of a market projected to exceed $100 billion by 2030.
Fisher Asset Management’s decision to increase its stake in Eli Lilly and Company (LLY) by 3.5% during the third quarter marks a significant reinforcement of institutional confidence in the pharmaceutical giant.
Beyond metabolic health, Eli Lilly’s recent regulatory successes in the Alzheimer’s space have further solidified its market position. The FDA approval of Kisunla (donanemab) provides a critical second pillar for the company’s long-term revenue growth. While the rollout of Alzheimer’s therapies is traditionally slower due to the need for specialized diagnostic infrastructure, Lilly’s established commercial footprint and deep pockets give it a distinct advantage over smaller biotech competitors. Fisher Asset Management’s increased exposure suggests a belief that these high-barrier-to-entry markets will provide durable, high-margin cash flows for the foreseeable future.
What to Watch
From a broader market perspective, Eli Lilly has transitioned from a traditional pharmaceutical stock into a high-growth healthcare technology hybrid. Its market capitalization, which has frequently surpassed that of major tech firms, reflects a shift in how investors value clinical innovation. The company’s ability to consistently beat earnings estimates while simultaneously investing heavily in R&D has created a virtuous cycle of growth. For institutional investors, LLY represents a core defensive holding that also offers the explosive growth typically reserved for the technology sector.
Looking ahead, the market will be closely watching Eli Lilly’s upcoming clinical data for triple-agonist therapies and its efforts to expand the indications for its existing GLP-1 portfolio into areas like sleep apnea and fatty liver disease. As institutional players like Fisher Asset Management continue to consolidate their positions, the focus will shift from clinical validation to operational execution. The ability to meet global demand and navigate evolving PBM (Pharmacy Benefit Manager) negotiations will be the next true test for the company’s valuation. For now, the signal from major asset managers is clear: Eli Lilly remains the cornerstone of the modern pharmaceutical investment thesis.
Sources
Sources
Based on 2 source articles- BbnsFisher Asset Management LLC Buys 150,595 Shares of Eli Lilly and Company $LLYMar 2, 2026
- The Lincolnian OnlineEli Lilly and Company $LLY Shares Acquired by Fisher Asset Management LLCMar 2, 2026